Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Methylphenidate and Alprazolam Co-Abuse: Drug-DNA Interactions

Version 1 : Received: 21 October 2020 / Approved: 23 October 2020 / Online: 23 October 2020 (10:36:07 CEST)

How to cite: Sharma, S.; Dutt, M.; Sharma, N.; Dharavath, R.N.; Kaur, T. Methylphenidate and Alprazolam Co-Abuse: Drug-DNA Interactions. Preprints 2020, 2020100481 (doi: 10.20944/preprints202010.0481.v1). Sharma, S.; Dutt, M.; Sharma, N.; Dharavath, R.N.; Kaur, T. Methylphenidate and Alprazolam Co-Abuse: Drug-DNA Interactions. Preprints 2020, 2020100481 (doi: 10.20944/preprints202010.0481.v1).

Abstract

Drug abuse is a major issue worldwide. Methylphenidate (MPH) and alprazolam (ALZ) are commonly prescribed drugs for the treatment of ADHD and anxiety disorders, respectively. The limited studies suggest that abusers primarily use benzodiazepines to counteract adverse effects associated with methylphenidate usage. The main aim of this study was to investigate the interaction of drugs with DNA using spectroscopic methods. Female Wistar rats were administered with MPH (10, 20, 40 mg/kg) and ALZ (5, 10, 20 mg/kg) alone and in combination for a period of 28 days. The FT-IR and UV results reveal some spectral changes in a dose-dependent manner, which indicates interactions of drugs with DNA. Thus, the changes in spectral peaks provide some insight into the mechanism of the interaction of drugs with DNA.

Subject Areas

Drug-DNA interaction; FTIR; Polydrug-abuse; UV-visible spectrophotometer

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.